Representative study shows growing acceptance of agribiotech


Adligenswil – A study conducted between 2000 and 2006 by Demoscope, a polling institute based in Adligenswil, confirmed that resistance to the application of gene technology in agriculture is slowly – but steadily – declining in Switzerland. With a representative selection of 2,008 interviewees from German- and French-speaking regions, the 2006 poll showed that 45% were against the use of gene technology in agriculture, 31% advocated it, while 24% were still undecided. The number of respondents expressing a negative attitude towards gene technology has decreased from 58% in 2000.
The most important differences in the single population groups concerned the French-speaking region in which opposing (31%) and advocating groups (33%) were almost equally strong. Generally greater acceptance of gene technology in agriculture was notable among interviewees under the age of 30. The authors conclude that the statistical reduction of resistance towards agribiotechnical applications may be due to better information: through increasing global experience with green gene technology, individuals originally identifying themselves as opponents have become more broadly informed. However, the increase in undecided individuals might point to the need for further public information.



Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...



Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....



Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...



Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...



Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...



Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...



Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody,...



Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...



Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2015 BIOCOM



All Events


Product of the week


Current issue

All issues